https://www.tipranks.com/news/the-fly/arcus-says-new-data-demonstrated-best-in-class-potential-for-casdatifan Canaccord reiterates a Buy rating on PacBio (PACB) with ...

PacBio (PACB) announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option covering 400,000 shares of PacBio common stock, and restricted ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 32.8% year on year to $39.22 million. Its non-GAAP ...

Piper Sandler lowered the firm’s price target on PacBio (PACB) to $2 from $2.50 following quarterly results. The firm keeps a Neutral rating on the shares. See what stocks are receiving strong ...

University of Washington & UDN Research: Demonstrated PacBio’s ability to simultaneously analyze the genome, methylome, epigenome, and transcriptome, providing novel insights into a rare and ...

Pacific Biosciences of California emphasized its strategic focus on expanding HiFi sequencing through product innovations like Vega and Revio. While macroeconomic uncertainties and academic ...

MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation ...

Pacific Biosciences of California ... a meaningful upgrade opportunity with approximately 125 active Sequel II and IIe users in the field, many of whom could transition to Revio for Vega in ...

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results ...

And welcome to the PacBio Fourth Quarter 2024 Earnings Conference ... upgrade opportunity with approximately 125 active Sequel II and IIe users in the field, many of whom could transition to ...